Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
THA903
- Development stage
- Preclinical
- Lead developer
- Theralpha
- Modality
- Peptides
- Administration
- Sublingual
01
Overview
**THA903** is a sublingually administered, nonopioid, water-soluble 11-amino acid peptide analgesic derived from hannalgesin, a neurotoxin isolated from king cobra (Ophiophagus hannah) venom. Developed by Theralpha S.A.S., it selectively targets pain pathways with potent preclinical efficacy demonstrated in acute pain models, offering a differentiated mechanism from opioids or NSAIDs. The peptide's mechanism of action involves modulation of neurotoxin-derived analgesic activity, though precise binding targets remain under investigation, positioning it as a novel candidate for non-addictive pain relief.[1][3][7][9][16]
- Other names
- TH-903TH903TH 903
Beyond the preview
Go deeper on THA903.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on THA903.